Home › NCT07579845

Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress

Who can join

Ages 40 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

1. Adult females or males age ≥ 40 years
2. Ability to read and speak English

Exclusion Criteria:

1. Current use of a dietary supplement containing fulvic or humic acid
2. Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella
3. Known allergies to any ingredients in the product
4. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
5. Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
6. Participants unable to provide consent

About the study

The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.

What is being tested

• Humic and Fulvic Acid Dietary Supplement (dietary supplement)

Sponsor: OvationLab · Participants: 60 · Started: May 5, 2026

Contact the study team

• Study Administrator · Phone: (240) 232-2103

Official record on ClinicalTrials.gov — NCT07579845

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.